

# CONFERENCE PROGRAMME

London Genetics 3rd Annual Pharmacogenetic Conference

## Stratified Medicine: Making it Happen

8th – 9th November 2011 Cumberland Lodge, Windsor, UK



Sponsored by:

*medco*<sup>®</sup>

**pwc**

 **BioStorage.**  
TECHNOLOGIES



**BioCentury**<sup>™</sup>

  
**opus**  
opusdc.co.uk

DAY 1 - Tuesday 8th November 2011

**12:00pm**

Arrival / Registration

Buffet Lunch

**1:00 - 1:10pm**

Introduction

- Elizabeth Foot, Chief Executive, London Genetics

**1:10 - 1:20pm**

The 2011 perspective on pharmacogenetics - the progress made and the challenges ahead

- Elizabeth Foot, Chief Executive, London Genetics
- Mark Caulfield, Director of William Harvey Research Institute & The NIHR Cardiovascular Biomedical Research Unit, Barts and The London Medical School Centre for Clinical Pharmacology and Clinical Director, London Genetics

SESSION 1

The value of pharmacogenetics in the clinic - today and where tomorrow?

Sponsored by Medco Healthcare Solutions Inc.

Chair: Elizabeth Foot, Chief Executive, London Genetics

**1:20 - 1:50pm**

**Pharmacogenetics and oral anticoagulation - where are we?**

- Munir Pirmohamed, NHS Chair of Pharmacogenetics, Head of Department of Molecular and Clinical Pharmacology, The Wolfson Centre for Personalized Medicine, University of Liverpool

**1:50 - 2:20pm**

**CYP2C19, clopidogrel and coronary heart disease: critical re-appraisal of the evidence and implications for future pharmacogenetic studies**

- Juan P. Casas, Senior Lecturer in Epidemiology, Department of Epidemiology and Population Health

**2:20 - 2:50pm**

Tea & Coffee

**2:50 - 3:20pm**

**Harnessing the value from integrated -omic approaches: discovery of novel biomarkers, prognostic factors and therapeutic targets in basal-like breast**

- Emanuele de Rinaldis, Senior Research Fellow and Team Leader, King's College London

**3:20 - 3:40pm**

**Type 2 diabetes: nature or nurture - the role of the epigenome**

- Graham Hitman, Professor of Molecular Medicine and Diabetes, Deputy Director Institute Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London

**3:40 - 4:10pm**

**Business models for the application of pharmacogenetics**

- Felix Frueh, VP, R&D Personalized Medicine, Medco Health Solutions, Inc.

## **SESSION 2**

**Making it happen: bringing pharmacogenetics to the clinic**

**4:10 - 4:15pm**

Chair: Steve DeCherney - Professor of Medicine, Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

**4:15 - 4:45pm**

**Open innovation in healthcare**

- Mike Barnes, Director of Bioinformatics, William Harvey Research Institute

**4:45 - 5:15pm**

**Medical University Warsaw: working at the cutting edge of science and translation medicine**

- Tomasz Stoklosa, Department of Immunology, Center of BioStructure Research, Medical University of Warsaw

**5:15 - 5:45pm**

**The Stratified Medicine Innovation Platform: a UK vision for stratified medicine**

- Zahid Latif, Head of Healthcare, Technology Strategy Board

**5:45pm**

Close day one

**6:30pm**

Pre-Dinner Drinks

**7:00pm**

Dinner

**After-dinner speaker: Moving from an art to a science - a brief history of medicine**

- Peter Donnelly, Professor of Statistical Science and Director of the Wellcome Trust Centre for Human Genetics, University of Oxford

## **DAY 2 Wednesday 9th November**

### **SESSION 3**

#### **Making pharmacogenetics part of the process - the view from industry**

**9:00 - 9:05am**

- Chair: Richard Watts, Marketing Manager Pharma/Biotech, Quiagen

**9:05 - 9:30am**

**Industry experience - the challenges in the development of targeted therapies**

- Adam Platt, Diagnostic Development Team Director, AstraZeneca

**9:30 - 9:55am**

**The biomarker is not the end**

- Michael Nohaile, Head Molecular Diagnostics, Novartis

**9:55 - 10:20am**

**Biomarkers in early clinical development: the CRO experience**

- Marie-Christine Bétard, Executive Director, Global Strategic Drug Development, Quintiles Innovation

**10:20 - 10:50am**

Tea & Coffee

**10:50 - 11:15am**

**How to do it: pharmacogenetics and biomarkers - clinical study and statistical design**

- Aiden Flynn, Director, Exploristics

**11:15 - 11:40am**

**Clinical studies with pharmacogenetic data: what are the regulators looking for? What are they ready to accept?**

- Bruno Flamion, Professor of Physiology and Pharmacology, University of Namur, Belgium and immediate past chair (2005-2010) of EMA's CHMP Scientific Advice Working Party

**11:40 - 12:05am**

**How to manage and interpret increasing amounts of genetic and biomarker data**

- Anthony Rowe, Principle Scientist - External Innovation in the R&D IT group of Janssen

**12:05 - 12:30pm**

**The ethics of personalised healthcare in a consumer age**

- Professor Jonathan Wolff, Department of Philosophy , University College London

**12:30 - 1:25pm**

Lunch

#### **SESSION 4**

**Pharmacogenetics in an era where cost-effectiveness is king**

Sponsored by PriceWaterhouseCooper

**1:25 - 1:30pm**

Chair: Steve Arlington, Global Pharmaceuticals and Life Sciences Advisory Leader, PriceWaterhouseCooper

**1:30 - 1:55pm**

**Pharmacogenetics and cost-effectiveness: a two-way street**

- Kate Moss, Director, PriceWaterhouseCooper

**1:55 - 2:20pm**

**Considerations for drug-diagnostic co-development - how to harness the value**

- Janette Thomas, Technology Officer, Integrated Medicines Ltd

**2:20 - 2:50pm**

Tea & Coffee

**2:50 - 3:15pm**

**Informed decision making: how pharmacogenetics can add value - or does it?**

- Katherine Payne, Professor of Health Economics, University of Manchester

**3:15 - 3:40pm**

**Pharmacogenetics and cost-effectiveness analysis: The evaluation of companion diagnostics**

- Elisabeth George, Associate Director, Technology Appraisals, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence

**3:40 - 3:55pm**

Discussion

**3:55 - 4:00pm**

**Closing comments**

- Elizabeth Foot, CEO London Genetics

**4:00pm**

Completion of evaluation forms and Close